Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 156189 | 4.32 |
09:34 ET | 57353 | 4.3243 |
09:36 ET | 92761 | 4.3781 |
09:38 ET | 37219 | 4.38 |
09:39 ET | 300178 | 4.39 |
09:41 ET | 29825 | 4.4178 |
09:43 ET | 89001 | 4.39 |
09:45 ET | 40787 | 4.375 |
09:48 ET | 24667 | 4.3801 |
09:50 ET | 27157 | 4.4 |
09:52 ET | 41452 | 4.405 |
09:54 ET | 58950 | 4.395 |
09:56 ET | 23013 | 4.38 |
09:57 ET | 38844 | 4.36 |
09:59 ET | 8963 | 4.37 |
10:01 ET | 73178 | 4.42 |
10:03 ET | 24158 | 4.415 |
10:06 ET | 20657 | 4.425 |
10:08 ET | 46302 | 4.415 |
10:10 ET | 8724 | 4.4112 |
10:12 ET | 78388 | 4.395 |
10:14 ET | 41129 | 4.385 |
10:15 ET | 46882 | 4.3701 |
10:17 ET | 19155 | 4.375 |
10:19 ET | 150932 | 4.39 |
10:21 ET | 184704 | 4.38 |
10:24 ET | 16100 | 4.41 |
10:26 ET | 27750 | 4.43 |
10:28 ET | 137077 | 4.43 |
10:30 ET | 22727 | 4.425 |
10:32 ET | 3064 | 4.425 |
10:33 ET | 61973 | 4.47 |
10:35 ET | 70315 | 4.4687 |
10:37 ET | 30796 | 4.465 |
10:39 ET | 50935 | 4.445 |
10:42 ET | 10354 | 4.43 |
10:44 ET | 8150 | 4.435 |
10:46 ET | 34202 | 4.42 |
10:48 ET | 18278 | 4.4397 |
10:50 ET | 63346 | 4.4 |
10:51 ET | 12561 | 4.395 |
10:53 ET | 12578 | 4.3811 |
10:55 ET | 19531 | 4.37 |
10:57 ET | 19592 | 4.375 |
11:00 ET | 49770 | 4.375 |
11:02 ET | 79780 | 4.375 |
11:04 ET | 25305 | 4.365 |
11:06 ET | 34174 | 4.39 |
11:08 ET | 37548 | 4.405 |
11:09 ET | 39659 | 4.415 |
11:11 ET | 89503 | 4.395 |
11:13 ET | 19183 | 4.405 |
11:15 ET | 23108 | 4.38 |
11:18 ET | 9102 | 4.37 |
11:20 ET | 40062 | 4.36 |
11:22 ET | 8507 | 4.365 |
11:24 ET | 10659 | 4.36 |
11:26 ET | 17513 | 4.355 |
11:27 ET | 36721 | 4.35 |
11:29 ET | 11167 | 4.345 |
11:31 ET | 93794 | 4.33 |
11:33 ET | 9933 | 4.325 |
11:36 ET | 27739 | 4.32 |
11:38 ET | 14277 | 4.31 |
11:40 ET | 20563 | 4.32 |
11:42 ET | 10000 | 4.3 |
11:44 ET | 2900 | 4.305 |
11:45 ET | 34578 | 4.3001 |
11:47 ET | 26583 | 4.305 |
11:49 ET | 2256 | 4.31 |
11:51 ET | 97309 | 4.305 |
11:54 ET | 7254 | 4.31 |
11:56 ET | 5821 | 4.31 |
11:58 ET | 7394 | 4.31 |
12:00 ET | 49274 | 4.3 |
12:02 ET | 9056 | 4.295 |
12:03 ET | 4460 | 4.3 |
12:05 ET | 7720 | 4.305 |
12:07 ET | 60253 | 4.315 |
12:09 ET | 7482 | 4.305 |
12:12 ET | 42050 | 4.305 |
12:14 ET | 13698 | 4.3199 |
12:16 ET | 700 | 4.32 |
12:18 ET | 38064 | 4.32 |
12:20 ET | 4733 | 4.315 |
12:21 ET | 6100 | 4.315 |
12:23 ET | 17342 | 4.305 |
12:25 ET | 1455 | 4.305 |
12:30 ET | 12278 | 4.305 |
12:32 ET | 1100 | 4.305 |
12:34 ET | 1000 | 4.305 |
12:36 ET | 2329 | 4.305 |
12:38 ET | 22379 | 4.315 |
12:39 ET | 22328 | 4.33 |
12:41 ET | 4360 | 4.325 |
12:43 ET | 3050 | 4.33 |
12:45 ET | 4800 | 4.325 |
12:48 ET | 15841 | 4.325 |
12:50 ET | 7774 | 4.3299 |
12:52 ET | 45539 | 4.3299 |
12:54 ET | 24852 | 4.335 |
12:56 ET | 11716 | 4.335 |
12:57 ET | 19679 | 4.3262 |
12:59 ET | 27743 | 4.325 |
01:01 ET | 17017 | 4.31 |
01:03 ET | 13140 | 4.305 |
01:06 ET | 14537 | 4.315 |
01:08 ET | 126616 | 4.295 |
01:10 ET | 3400 | 4.29 |
01:12 ET | 5893 | 4.2959 |
01:14 ET | 6056 | 4.295 |
01:15 ET | 7948 | 4.295 |
01:17 ET | 6593 | 4.29 |
01:19 ET | 42872 | 4.285 |
01:21 ET | 22638 | 4.2963 |
01:24 ET | 6745 | 4.285 |
01:26 ET | 18800 | 4.285 |
01:28 ET | 24811 | 4.295 |
01:30 ET | 16086 | 4.305 |
01:32 ET | 158583 | 4.32 |
01:33 ET | 50474 | 4.3375 |
01:35 ET | 10119 | 4.355 |
01:37 ET | 10076 | 4.355 |
01:39 ET | 72388 | 4.37 |
01:42 ET | 71711 | 4.34 |
01:44 ET | 116257 | 4.33 |
01:46 ET | 4178 | 4.335 |
01:48 ET | 12866 | 4.325 |
01:50 ET | 26809 | 4.33 |
01:51 ET | 9000 | 4.33 |
01:53 ET | 21414 | 4.3375 |
01:55 ET | 15665 | 4.33 |
01:57 ET | 4998 | 4.32 |
02:00 ET | 400 | 4.325 |
02:02 ET | 54037 | 4.34 |
02:04 ET | 25702 | 4.35 |
02:06 ET | 10431 | 4.345 |
02:08 ET | 8706 | 4.36 |
02:09 ET | 58444 | 4.345 |
02:11 ET | 7144 | 4.345 |
02:13 ET | 214809 | 4.325 |
02:15 ET | 11032 | 4.33 |
02:18 ET | 5373 | 4.335 |
02:20 ET | 11348 | 4.325 |
02:22 ET | 11305 | 4.325 |
02:24 ET | 7198 | 4.325 |
02:26 ET | 15024 | 4.315 |
02:27 ET | 10729 | 4.31 |
02:29 ET | 1800 | 4.3198 |
02:31 ET | 16799 | 4.325 |
02:33 ET | 3920 | 4.33 |
02:36 ET | 9360 | 4.32 |
02:38 ET | 2915 | 4.33 |
02:40 ET | 26318 | 4.335 |
02:42 ET | 158300 | 4.36 |
02:44 ET | 48507 | 4.355 |
02:45 ET | 2300 | 4.355 |
02:47 ET | 63962 | 4.345 |
02:49 ET | 3205 | 4.34 |
02:51 ET | 7113 | 4.345 |
02:54 ET | 34943 | 4.335 |
02:56 ET | 2883 | 4.33 |
02:58 ET | 9978 | 4.335 |
03:00 ET | 2300 | 4.335 |
03:02 ET | 51904 | 4.3433 |
03:03 ET | 11191 | 4.34 |
03:05 ET | 18112 | 4.34 |
03:07 ET | 24107 | 4.345 |
03:09 ET | 6691 | 4.35 |
03:12 ET | 8028 | 4.35 |
03:14 ET | 4463 | 4.34 |
03:16 ET | 16557 | 4.345 |
03:18 ET | 11098 | 4.35 |
03:20 ET | 72993 | 4.33 |
03:21 ET | 7243 | 4.335 |
03:23 ET | 2657 | 4.335 |
03:25 ET | 8809 | 4.335 |
03:27 ET | 91506 | 4.335 |
03:30 ET | 2014 | 4.335 |
03:32 ET | 17159 | 4.34 |
03:34 ET | 14814 | 4.34 |
03:36 ET | 5285 | 4.335 |
03:38 ET | 23778 | 4.335 |
03:39 ET | 11602 | 4.33 |
03:41 ET | 21588 | 4.33 |
03:43 ET | 119005 | 4.325 |
03:45 ET | 23285 | 4.325 |
03:48 ET | 22808 | 4.325 |
03:50 ET | 14109 | 4.33 |
03:52 ET | 49177 | 4.32 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.5B | -12.5x | --- |
Celldex Therapeutics Inc | 2.4B | -13.6x | --- |
Apogee Therapeutics Inc | 2.3B | -19.1x | --- |
Agios Pharmaceuticals Inc | 2.4B | -6.9x | --- |
Structure Therapeutics Inc | 2.2B | -17.3x | --- |
Iovance Biotherapeutics Inc | 2.2B | -4.4x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.5B |
---|---|
Revenue (TTM) | $520.0K |
Shares Outstanding | 593.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.48 |
EPS | $-0.35 |
Book Value | $0.46 |
P/E Ratio | -12.5x |
Price/Sales (TTM) | 4,836.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -40,381.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.